Individualized Prophylaxis for Severe Hemophilia A Children

Hemophilia Clinical Trial

Official title:

Individualized Tertiary Low Dose Prophylaxis for Severe Hemophilia A Children With Arthropathy in China

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02116855
• Other study ID #: BCH-20140415
• Status: Not yet recruiting
• Phase: N/A
• First received: April 15, 2014
• Last updated: April 15, 2014
• Start date: June 2014

Study information

• Verified date: April 2014
• Source: Beijing Children's Hospital
• Contact: Hui R Wu, MD
• Phone: 8613911383480
• Email: runhuiwu[@]hotmail.com
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

A multi centre two year long term escalating dose tertiary prophylaxis study on the efficacy and cost saving of individualized low dose prophylaxis regimens for boys with severe hemophilia A in China staring with a low dose regimen in step I, an escalated low dose regimen in step II and a tailored dose regimen based on individual PK profiles in step III. The dose escalation criteria are adjusted according to patterns and frequencies of joint bleeding and assessed in each subject every 3 months. Efficacy of the 3 different dose regimens are measured by the Annualized Joint Bleeding rate (AJBR) as a primary end point and the Hemophilia Joint Health Score (HJHS ) and QoL scores (CHO-KLAT and PedsQoL) , image studies of target joints by Ultrasound, X-ray and MRI examinations, consumption of factor VIII and inhibitor rates as secondary end points.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 6 Years to 10 Years

Eligibility

Inclusion Criteria:

1. Severe hemophilia A with FVIII <1 %

2. Age from 6 to 10 years

3. Patients with more than 50 exposure day (ED)

4. Patients with one or more target joints (a target joint is defined as a joint with 3 or more bleeds in a consecutive 3 months) or disease joints (defined as presence of visible joint swelling and /or limitation of movements and/or joint deformities in the absent of an acute joint bleed )

5. on-demand treatment more than 12months before the study

Exclusion Criteria:

1. A history of FVIII inhibitor (titer greater than 0.6 BU) and detectable FVIII inhibitor at screening (titer greater than 0.6 BU)

2. Chronic renal failure (serum creatinine greater than 2.0 mg /dL)

3. Chronic Liver disease (ALT greater than 200 U/L))

4. Patients with clinically documented immunodeficiencies

5. Patients anticipated to require Major surgery

6. Patients with competing high risks such as symptomatic HIV infection, Juvenile rheumatoid arthritis, metabolic bone diseases, or other diseases known to mimic or cause joint diseases

7. Patients live too far from the comprehensive care centre at BCH and had demonstrated previous non compliance to therapies or clinical studies

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hemophilia
• Hemophilia A

Intervention

Other:
• according to the efficacy of AJBRs

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Children's Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AJBRs (annualized Joint bleeding rates)		three months	No